Patent application EP19169841A (EP), filed 2019-04-17
Publication number: EP3725888A1
Title: ONCOLYTIC ADENOVIRAL VECTOR EXPRESSING PEPTIDYLARGININE DEIMINASE AND TISSUE INHIBITOR OF METALLOPROTEINASE
Abstract: The present invention relates to cancer therapies. More specifically, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to a use of said vectors in the manufacture of a medicament for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to methods of producing peptidylarginine deiminase and TIMP in a cell and increasing anti-tumor effect and induction of specific immune response in a subject, as well as uses of the oncolytic adenoviral vector of the invention for producing transgenes in a cell and increasing anti-tumor effect and generation of specific immune response in a subject.
IPC codes: A61K  48/    00            A I
C12N  15/   861            A I
Claims: number: 1
text: An oncolytic adenoviral vector comprising an adenovirus serotype 5 (Ad5) nucleic acid backbone, a 24 bp deletion (D24) in the Rb binding constant region 2 of E1, a nucleic acid sequence encoding a peptidylarginine deiminase and a nucleic acid sequence encoding TIMP in the E3 region.
number: 2
text: The oncolytic adenoviral vector according to claim 1, wherein peptidylarginine deiminase and TIMP are connected with IRES.
number: 3
text: The oncolytic adenoviral vector according to claim 1, wherein peptidylarginine deiminase and TIMP are connected with P2A.
number: 4
text: The oncolytic adenoviral vector according to any one of claims 1-3, wherein peptidylarginine deiminase and TIMP are placed under E3 promoter.
number: 5
text: The oncolytic adenoviral vector according to any one of claims 1-3, wherein peptidylarginine deiminase and TIMP are placed under CMV(Cuo) promoter.
number: 6
text: The oncolytic adenoviral vector according to any one of claims 1-5, wherein peptidylarginine deiminase is PADI1 and TIMP is TIMP2.
number: 7
text: The oncolytic adenoviral vector according to any one of claims 1-6 comprising a native E1 A promoter.
number: 8
text: The oncolytic adenoviral vector according to any one of claims 1-7 further comprising an Ad5/3 chimerism as a capsid modification.
number: 9
text: The oncolytic adenoviral vector according to any one of claims 1-2 or 4-8 comprising a nucleotide sequence having at least 70% identity to SEQ ID NO: 1 or according to any of claims 3-4 or 5-8 comprising a nucleotide sequence having at least 70% identity to SEQ ID NO:2.
number: 10
text: A cell comprising the adenoviral vector according to any one of claims 1-9.
number: 11
text: A pharmaceutical composition comprising the adenoviral vector according to any one of claims 1-9.
number: 12
text: The adenoviral vector according to any one of claims 1-9 for use in the treatment of cancer or in the manufacture of a medicament for treating cancer in a subject.
number: 13
text: The adenoviral vector for use according to claim 12, wherein the cancer is selected from a group consisting of nasopharyngeal cancer, synovial cancer, hepatocellular cancer, renal cancer, cancer of connective tissues, melanoma, lung cancer, bowel cancer, colon cancer, rectal cancer, colorectal cancer, brain cancer, throat cancer, oral cancer, liver cancer, bone cancer, pancreatic cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, T-cell leukemia/lymphoma, neuroma, von Hippel-Lindau disease, Zollinger-Ellison syndrome, adrenal cancer, anal cancer, bile duct cancer, bladder cancer, ureter cancer, brain cancer, oligodendroglioma, neuroblastoma, meningioma, spinal cord tumor, bone cancer, osteochondroma, chondrosarcoma, Ewing's sarcoma, cancer of unknown primary site, carcinoid, carcinoid of gastrointestinal tract, fibrosarcoma, breast cancer, Paget's disease, cervical cancer, colorectal cancer, rectal cancer, esophagus cancer, gall bladder cancer, head cancer, eye cancer, neck cancer, kidney cancer, Wilms' tumor, liver cancer, Kaposi's sarcoma, prostate cancer, lung cancer, testicular cancer, Hodgkin's disease, non-Hodgkin's lymphoma, oral cancer, skin cancer, mesothelioma, multiple myeloma, ovarian cancer, endocrine pancreatic cancer, glucagonoma, pancreatic cancer, parathyroid cancer, penis cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymus cancer, thyroid cancer, trophoblastic cancer, hydatidiform mole, uterine cancer, endometrial cancer, vagina cancer, vulva cancer, acoustic neuroma, mycosis fungoides, insulinoma, carcinoid syndrome, somatostatinoma, gum cancer, heart cancer, lip cancer, meninges cancer, mouth cancer, nerve cancer, palate cancer, parotid gland cancer, peritoneum cancer, pharynx cancer, pleural cancer, salivary gland cancer, tongue cancer and tonsil cancer.
number: 14
text: The adenoviral vector for use according to claim 12 or 13, wherein the treatment of cancer in a subject is conducted through an intratumoral, intramuscular, intra-arterial, intravenous, intrapleural, intravesicular, intracavitary or peritoneal injection, or an oral administration.
number: 15
text: The adenoviral vector for use according to claim 14, wherein the injection or the administration is conducted several times during the treatment period, or wherein an oncolytic adenoviral vector having a different fiber knob of the capsid compared to the vector of the earlier treatment is used.
number: 16
text: The adenoviral vector for use according to any one of claims 12-15, wherein the treatment of cancer in a subject further comprises an administration of a checkpoint inhibitor, verapamil or another calcium channel blocker, autophagy inducing agents, temozolomide, chemotherapy or anti-CD20 therapy or other approaches for blocking of neutralizing antibodies, substances capable to downregulating regulatory T-cells in a subject to a subject.
number: 17
text: A method of producing peptidylarginine deiminase and TIMP in a cell in vitro, wherein the method comprises:
number: 18
text: A use of the oncolytic adenoviral vector according to any one of claims 1-9 for producing peptidylarginine deiminase and TIMP in a cell in vitro.
Office action: search_report, dated 2020-10-21
Prior art cited: ref_id: EP2379586A1
ref_type: patent
severity: background
ref_id: US2016339066A1
ref_type: patent
severity: background
ref_id: WO2014055960A1
ref_type: patent
severity: background
ref_id: - BOURBOULIA, D.; HAN, H.; JENSEN-TAUBMAN, S.; GAVIL, N.; ISAAC, B.; WEI, B.; NECKERS, L.; STETLER-STEVENSON, W. G.: "TIMP-2 modulates cancer cell transcriptional profile and enhances E-cadherin/beta-catenin complex expression in A549 lung cancer cells", ONCOTARGET, vol. 4, 2013, pages 166 - 76
ref_type: npl
severity: background
ref_id: - FEUN, L.; SAVARAJ, N.: "Pegylated arginine deiminase: a novel anticancer enzyme agent", EXPERT OPIN INVESTIG DRUGS, vol. 15, 2006, pages 815 - 22, XP055216986, DOI: doi:10.1517/13543784.15.7.815
ref_type: npl
severity: background
ref_id: - JAHANI, M.; NOROZNEZHAD, F.; MANSOURI, K.: "Arginine: Challenges and opportunities of this two-faced molecule in cancer therapy", BIOMED PHARMACOTHER, vol. 102, 2018, pages 594 - 601
ref_type: npl
severity: background
ref_id: - PARK, I. S.; KANG, S. W.; SHIN, Y. J.; CHAE, K. Y.; PARK, M. 0.; KIM, M. Y.; WHEATLEY, D. N.; MIN, B. H.: "Arginine deiminase: a potential inhibitor of angiogenesis and tumour growth", BR J CANCER, vol. 89, 2003, pages 907 - 14, XP002369974, DOI: doi:10.1038/sj.bjc.6601181
ref_type: npl
severity: background
ref_id: - SEO, D.-W.; LI, H.; GUEDEZ, L.; WINGFIELD, P. T.; DIAZ, T.; SALLOUM, R.; WEI, B.-Y.; STETLER-STEVENSON, W. G.: "TIMP-2 Mediated Inhibition of Angiogenesis", CELL, vol. 114, 2003, pages 171 - 180, XP002313229, DOI: doi:10.1016/S0092-8674(03)00551-8
ref_type: npl
severity: background
ref_id: WO2010072900A1
ref_type: patent
severity: background
ref_id: - JIANG HUI ET AL: "Arginine deiminase expressed in vivo, driven by human telomerase reverse transcriptase promoter, displays high hepatoma targeting and oncolytic efficiency", ONCOTARGET, vol. 8, no. 23, 6 June 2017 (2017-06-06), pages 37694 - 37704, XP002794373
ref_type: npl
severity: background
ref_id: - LAMFERS MARTINE L M ET AL: "Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity In vivo without affecting antitumor efficacy in malignant glioma", CANCER RESEARCH, vol. 65, no. 20, October 2005 (2005-10-01), pages 9398 - 9405, XP002794374, ISSN: 0008-5472
ref_type: npl
severity: background
ref_id: WO2010072900
ref_type: patent
severity: background
ref_id: - JIANG HUI ET AL, "Arginine deiminase expressed in vivo, driven by human telomerase reverse transcriptase promoter, displays high hepatoma targeting and oncolytic efficiency", ONCOTARGET, (20170606), vol. 8, no. 23, pages 37694 - 37704, XP002794373 [A] 1-18 * abstract * * page  37698 * * page  37702, column  1, paragraph  3 *
ref_type: npl
severity: background
ref_id: - LAMFERS MARTINE L M ET AL, "Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity In vivo without affecting antitumor efficacy in malignant glioma", CANCER RESEARCH, (200510), vol. 65, no. 20, ISSN 0008-5472, pages 9398 - 9405, XP002794374 [A] 1-18 * abstract * * page  9399, column  1, paragraph  4  - page  9400, column  1, paragraph  1 * * page  9400, column  1, paragraph  5  - page  9403, column  1, paragraph  1 *
ref_type: npl
severity: background
Final disposition: pending (2020-10-21)